CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Axsome Therapeutics, Inc.

AXSM
$10.32BLarge Cap

Next catalyst

PDUFAMay 1, 2027in 165 days

AXS-12 (reboxetine)

Narcolepsy

Get an email about AXSM's next catalysts

Track Axsome Therapeutics (AXSM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 3 more upcoming events in our data (Phase 2 readout, Phase 3 readout, NDA filing).See the timeline

Catalyst Timeline

4 upcoming, 1 past

Phase 2

Solriamfetol Phase 2 Est. Readout (SOLARIMS)

December 2026~Solriamfetol46

Estimated primary completion for Solriamfetol trial (NCT06170970) in Multiple Sclerosis. Topline data typically follows completion by weeks to months.

Source
Phase 3

Solriamfetol Phase 3 Est. Readout

December 2026~Solriamfetol520

Estimated primary completion for Solriamfetol trial (NCT06413433) in Binge-Eating Disorder. Topline data typically follows completion by weeks to months.

Source
NDA Filing

NDA Filing — AXS-12

May 1, 2027

Axsome Therapeutics announced plans to file one NDA per year through 2030, with AXS-12 targeting a May 1, 2027 PDUFA date. This signals the company's expected regulatory pipeline progression over the next several years.

Source
PDUFANext

FDA PDUFA Date AXS-12

May 1, 2027AXS-12 (reboxetine)

NDA filing. AI-extracted from news: Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA

Source

Upcoming FDA decisions

How AXSM's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK816 employees

Frequently asked questions

What is in Axsome Therapeutics, Inc.'s drug pipeline?→

CatalystAlert tracks 14 drug candidates in Axsome Therapeutics, Inc.'s (AXSM) pipeline across Phase 3, Phase 2. Its lead program is AXS-12 (reboxetine) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Axsome Therapeutics, Inc.'s next FDA catalyst?→

Axsome Therapeutics, Inc.'s (AXSM) next tracked catalyst is a PDUFA date expected May 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track AXSM biotech catalysts?→

Add AXSM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Axsome Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply